Filing identity and reporting period
Important identity mismatch: The supplied filing is Helix Acquisition Corp.’s Form 10-Q, not a Moonlake Immunotherapeutics filing. It therefore contains no Moonlake-specific operating or financial information. The report covers the period from Helix’s inception on August 13, 2020 through September 30, 2020; the statements are unaudited.
Business context and key financial metrics
Helix was a newly formed Cayman Islands blank-check company seeking a business combination. It had not commenced operations by September 30, 2020 and reported no revenue. Its sole reported expense was $5,000 of formation and operating costs, resulting in a $5,000 net loss. Basic and diluted loss per share was reported as $0.00 rounded.
- Assets: $163,513, entirely deferred offering costs.
- Liabilities: $143,513 current, including $90,450 accrued offering costs and a $53,063 related-party promissory note.
- Shareholders’ equity: $20,000.
- Cash and operating cash flow: No cash at September 30; net cash used in operating activities was zero because formation costs were funded through sponsor share issuance.
- Debt and liquidity: No long-term debt was reported. The related-party note was non-interest-bearing; it was due on the earlier of December 31, 2020 or the IPO, and was due on demand after the IPO under the filing’s subsequent-event disclosure.
- Margins: Not meaningful; the company had no revenue.
Material changes and subsequent events
There is no comparable prior-period operating result because the company was formed during this reporting period. After quarter-end, on October 22, 2020, Helix completed an IPO of 11.5 million public shares at $10 each, raising $115.0 million, and a private placement raising $4.3 million. It placed $115.0 million in a trust account and reported $1,646,100 in cash outside the trust after offering costs. Total transaction costs were $6,750,447, including $4,025,000 of deferred underwriting fees payable only if a business combination is completed.
Outlook, risks, and contingencies
Management expected to incur additional public-company and target-search costs and did not expect operating revenue before a business combination. It stated that it did not expect to need additional funds for planned expenditures, but warned that higher-than-estimated search and transaction costs could leave insufficient working capital and that additional financing might be needed. Helix had 24 months from the IPO closing to complete a business combination or redeem public shares and wind up. Completion was not assured.
The filing notes potential adverse effects from COVID-19 on the company’s financial position and target search, though the specific impact was not determinable. Other disclosed risks include possible negative interest rates reducing trust assets and redemption value, third-party claims against trust funds subject to the sponsor’s limited indemnity, shareholder redemptions, and the possibility that liquidation distributions could be below the $10 IPO price. No legal proceedings were reported. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Most important facts to verify
- Confirm the intended issuer: this filing is for Helix Acquisition Corp., not Moonlake Immunotherapeutics.
- For Helix, verify subsequent IPO and trust-account details against its October 2020 filings; those events occurred after the September 30 balance-sheet date.
- Review the IPO prospectus for the full risk factors, redemption terms, sponsor protections, and business-combination conditions.
- Check later filings for the outcome of the business-combination search, financing needs, and any changes to trust assets or deadlines.